Iovance Biotherapeutics (IOVA) Up 11% Since Q1 2026, Does it Have Further Upside Potential?

The share price of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has improved more than 11% since the company reported its fiscal Q1 2026 earnings on May 7. Wall Street has also adopted a bullish stance on the stock. For instance, recently on June 1, Citizens reiterated a Market Outperform rating on the stock with a price target of $5. Overall, analysts’ 12-month average price target reflects more than 130% upside. The stock is also ranked among our one of the Best Penny Stocks with Huge Upside Potential.

​During the fiscal Q1 2026, Iovance reported total revenue of $71 million, reflecting a 45% increase year-over-year. Management noted that the increase was driven by roughly $60 million in revenue from its flagship cancer therapy Amtagvi and around $11 million from Proleukin. In addition, the gross margins came in at 41%, absorbing some one-time costs from facility maintenance and expansion.

​Looking ahead, management has guided for roughly $86 million to $88 million in revenue for the second quarter and roughly $350 million to $370 million for the full year. Iovance also highlighted that Amtagvi’s commercial momentum is building. Management highlighted the real-world response rates of 52% in earlier-stage patients and a median response duration of 3 years in heavily treated patients. Moreover, the treatment network has grown to over 90 authorized centers across the US and Canada, with at least 110 expected by year-end.

​Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) is a commercial-stage biopharmaceutical company focused on developing and commercializing tumor-infiltrating lymphocyte cell therapies for metastatic melanoma and other solid tumor cancers.

READ NEXT: 9 Most Undervalued Foreign Stocks to Buy Now and 10 Most Undervalued US Stocks According to Hedge Funds. 

Disclosure: None. Follow Insider Monkey on Google News.